Investors seeking to outperform the market often focus on hand-picking stocks. Selecting the right ones has proven to be a key factor in boosting wealth.
After finishing at $1.33 in the prior trading day, Outlook Therapeutics Inc (NASDAQ: OTLK) closed at $1.28, down -3.76%. In other words, the price has decreased by -$3.76 from its previous closing price. On the day, 0.77 million shares were traded. OTLK stock price reached its highest trading level at $1.33 during the session, while it also had its lowest trading level at $1.2612.
Ratios:
Our goal is to gain a better understanding of OTLK by taking a closer look at its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 0.54 and its Current Ratio is at 0.67.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, OTLK now has a Market Capitalization of 56856996 and an Enterprise Value of 82653888. For the stock, the TTM Price-to-Sale (P/S) ratio is 37.66. Its current Enterprise Value per Revenue stands at 54.908 whereas that against EBITDA is -1.14.
Stock Price History:
The Beta on a monthly basis for OTLK is 0.63, which has changed by -0.7777778 over the last 52 weeks, in comparison to a change of 0.20772064 over the same period for the S&P500. Over the past 52 weeks, OTLK has reached a high of $6.98, while it has fallen to a 52-week low of $0.79. The 50-Day Moving Average of the stock is -1.53%, while the 200-Day Moving Average is calculated to be -21.40%.
Shares Statistics:
The stock has traded on average 3.80M shares per day over the past 3-months and 1205000 shares per day over the last 10 days, according to various share statistics. A total of 43.48M shares are outstanding, with a floating share count of 29.09M. Insiders hold about 34.52% of the company’s shares, while institutions hold 13.63% stake in the company. Shares short for OTLK as of 1760486400 were 2168058 with a Short Ratio of 0.57, compared to 1757894400 on 5354593. Therefore, it implies a Short% of Shares Outstanding of 2168058 and a Short% of Float of 5.9299998.
Earnings Estimates
Outlook Therapeutics Inc (OTLK) is currently under the scrutiny of 4.0 analysts, each contributing to the ongoing evaluation of its stock.The consensus estimate for the next quarter is -$0.21, with high estimates of -$0.09 and low estimates of -$0.33.
Analysts are recommending an EPS of between -$1.72 and -$1.92 for the fiscal current year, implying an average EPS of -$1.84. EPS for the following year is -$1.01, with 4.0 analysts recommending between -$0.28 and -$1.67.
Revenue Estimates
For the next quarter, 4 analysts are estimating revenue of $4.4M. There is a high estimate of $5M for the next quarter, whereas the lowest estimate is $3.8M.
Based on 5 analysts’ estimates, the company’s revenue will be $29.78M in the next fiscal year. The high estimate is $60.88M and the low estimate is $15.92M.
